| General Information | |
|---|---|
| ZINC ID | ZINC000103247944 |
| Molecular Weight (Da) | 401 |
| SMILES | C[C@](O)(CNC(=O)c1cnc(OCC2CC2)c(-c2ccc(Cl)cc2)c1)C1CC1 |
| Molecular Formula | C22Cl1N2O3 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 108.58 |
| HBA | 4 |
| HBD | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 28 |
| LogP | 3.93 |
| Activity (Ki) in nM | 34.6737 |
| Polar Surface Area (PSA) | 71.45 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 0.765 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.45 |
| Ilogp | 3.92 |
| Xlogp3 | 3.75 |
| Wlogp | 3.96 |
| Mlogp | 3.1 |
| Silicos-it log p | 4.76 |
| Consensus log p | 3.9 |
| Esol log s | -4.41 |
| Esol solubility (mg/ml) | 0.0156 |
| Esol solubility (mol/l) | 0.0000388 |
| Esol class | Moderately |
| Ali log s | -4.94 |
| Ali solubility (mg/ml) | 0.00457 |
| Ali solubility (mol/l) | 0.0000114 |
| Ali class | Moderately |
| Silicos-it logsw | -6.69 |
| Silicos-it solubility (mg/ml) | 0.000082 |
| Silicos-it solubility (mol/l) | 0.0000002 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.08 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.62 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.281 |
| Logd | 3.739 |
| Logp | 4.883 |
| F (20%) | 0.002 |
| F (30%) | 0.021 |
| Mdck | - |
| Ppb | 97.96% |
| Vdss | 1.528 |
| Fu | 0.94% |
| Cyp1a2-inh | 0.415 |
| Cyp1a2-sub | 0.392 |
| Cyp2c19-inh | 0.88 |
| Cyp2c19-sub | 0.157 |
| Cl | 4.284 |
| T12 | 0.081 |
| H-ht | 0.564 |
| Dili | 0.813 |
| Roa | 0.84 |
| Fdamdd | 0.846 |
| Skinsen | 0.082 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.17 |
| Bcf | 1.776 |
| Igc50 | 4.663 |
| Lc50 | 5.533 |
| Lc50dm | 5.677 |
| Nr-ar | 0.034 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.62 |
| Nr-aromatase | 0.899 |
| Nr-er | 0.185 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.04 |
| Sr-are | 0.476 |
| Sr-atad5 | 0.054 |
| Sr-hse | 0.623 |
| Sr-mmp | 0.63 |
| Sr-p53 | 0.614 |
| Vol | 399.962 |
| Dense | 1 |
| Flex | 0.474 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 3 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.7 |
| Synth | 2.935 |
| Fsp3 | 0.455 |
| Mce-18 | 77.625 |
| Natural product-likeness | -0.943 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |